News
RVTY
119.05
-0.94%
-1.13
Revvity Is Maintained at Outperform by Leerink Partners
Dow Jones · 12h ago
Revvity Price Target Raised to $135.00/Share From $130.00 by Leerink Partners
Dow Jones · 12h ago
Wednesday Sector Laggards: Healthcare, Technology & Communications
NASDAQ · 1d ago
Stocks Settle Higher on Positive Corporate Earnings Results
Barchart · 1d ago
S&P 500 Movers: ULTA, UAL
NASDAQ · 1d ago
Ex-Dividend Reminder: GE HealthCare Technologies, Revvity and First Busey
NASDAQ · 1d ago
Big banks, UnitedHealth report quarterly earnings: Morning Buzz
TipRanks · 2d ago
Assessing Revvity: Insights From 8 Financial Analysts
Benzinga · 2d ago
Etsy, Enphase downgraded: Wall Street’s top analyst calls
TipRanks · 2d ago
Revvity Price Target Raised to $140.00/Share From $125.00 by Barclays
Dow Jones · 2d ago
Revvity Raised to Overweight From Equal-Weight by Barclays
Dow Jones · 2d ago
Barclays Upgrades Revvity to Overweight, Raises Price Target to $140
Benzinga · 2d ago
Barclays upgrades Revvity, says stock ‘checks most of the boxes’
TipRanks · 2d ago
Revvity Ramps Up R&D Spending Since PerkinElmer Split
The Wall Street Journal · 2d ago
Weekly Report: what happened at RVTY last week (1007-1011)?
Weekly Report · 3d ago
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
NASDAQ · 10/07 15:31
Press Release: Revvity To Hold Earnings Call on Monday, November 4, 2024
Dow Jones · 10/07 12:06
Weekly Report: what happened at RVTY last week (0930-1004)?
Weekly Report · 10/07 09:04
Revvity, Inc. (NYSE:RVTY) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Simply Wall St · 10/03 13:20
Weekly Report: what happened at RVTY last week (0923-0927)?
Weekly Report · 09/30 09:04
More
Webull provides a variety of real-time RVTY stock news. You can receive the latest news about Revvity Inc through multiple platforms. This information may help you make smarter investment decisions.
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.